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Abstract: Nanoparticles have received much attention recently due to their use in cancer 
therapy. Studies have shown that different metal oxide nanoparticles induce cytotoxicity in 
cancer cells, but not in normal cells. In some cases, such anticancer activity has been 
demonstrated to hold for the nanoparticle alone or in combination with different therapies, 
such as photocatalytic therapy or some anticancer drugs. Zinc oxide nanoparticles have been 
shown to have this activity alone or when loaded with an anticancer drug, such as 
doxorubicin. Other nanoparticles that show cytotoxic effects on cancer cells include cobalt 
oxide, iron oxide and copper oxide. The antitumor mechanism could work through the 
generation of reactive oxygen species or apoptosis and necrosis, among other possibilities. 
Here, we review the most significant antitumor results obtained with different metal  
oxide nanoparticles. 
Keywords: antitumor; cancer therapy; metal oxide nanoparticles; in vitro; in vivo 
 
1. Introduction 
Cancer is one of the principal causes of mortality worldwide and represents a serious health problem. 
The last World Cancer Report of the World Health Organization states that the incidence of cancer 
increased from 12.7 million in 2008 to 14.1 million in 2012. This trend is projected to continue, with the 
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number of new cases per year expected to rise a further 75% over the next two decades, which will bring 
the number of new cancer cases close to 25 million per year [1]. 
The treatment of cancer involves different therapies based on alkylating agents, antimetabolites, 
biological agents, etc.; but one of the principal problems is the side effects due to difficulties in 
differentiating between cancerous and normal cells, which produces systemic toxicity [2]. 
When exploring new strategies for the treatment of cancer, one possibility is the use of nanomaterials. 
For more than 30 years, nanomaterials have been used as pharmaceutical carriers to enhance the in vivo 
antitumor efficacy of drugs. The first studies in the 1970s used nanoscale drug carriers, such as liposomes 
entrapping antitumor pharmaceuticals. 
The development of nanostructured devices for drug delivery and controlled release constituted  
new antitumor chemotherapies [3]. Recently, a systematic review was conducted in order to retrieve 
studies of the therapeutic effects of nanoparticles loaded with chemotherapeutic agents in digestive 
cancer tumors [4]. 
There is, however, a growing field of research into the use of nanoparticles (NPs) against tumor 
formation, development and progression, due to their intrinsic antitumor effects. The physicochemical 
properties that give NPs their anticancer activity are either related to intrinsic features, such as their 
antioxidant action, or depend on activities based on the application of external stimuli, such as 
hyperthermia in response to the application of infrared rays or magnetic fields. NPs with such properties 
may be used to play different roles in therapeutic antitumor approaches in photodynamic therapy and in 
hyperthermia. NPs stimulated by an external radiation source produce free radicals that kill cancer cells. 
In the case of radiotherapy, NPs may act as co-adjuvant agents, increasing the cell killing effect of 
ionizing radiation specifically on tumor cells. NPs may also act on the tumor environment, such as blood 
vessels or stroma, to reduce the development of tumor mass. Finally, NPs have been demonstrated to 
reduce the rate of tumor progression as a consequence of their antioxidant capacities [5]. 
The efficient carrier properties of NPs have enhanced their use in cancer treatment. NPs can be used 
to treat cancer by either passive or active processes. A passive process takes advantage of the enhanced 
permeability and retention (EPR) effect. The leaky vasculature found in cancerous tissue enables NPs to 
diffuse easily into the cancerous tissue and kill cells [6]. There are some side effects associated with 
drug delivery through passive processes. The leaky vasculature found in the cancerous cell is also found 
in inflamed tissue; as a result, there can be no strictly targeted drug delivery. The side effects this leads 
to can be reduced by targeting the drug through active processes. In an active process, the NPs are 
functionalized and targeted at the cancerous cell. Binding biomolecules or a ligand as a receptor to NPs 
can increase delivery to the targeted cancerous cells instead of normal cells. In anticancer therapy 
research, metal oxide NPs are used experimentally to directly kill tumor cells in vitro and in vivo. The 
results obtained with different metal oxide NPs are presented in this review, and their mechanisms of 
action are considered. 
1.1. Iron Oxide 
The tumor cell can be directly killed by non-toxic wavelength radiation, such as near-infrared (NIR), 
or oscillating magnetic fields (MF) that can be absorbed and transformed into toxic stimuli of reactive 
oxygen species (ROS) production or hyperthermia by NPs of iron oxide [7]. The advantage of this 
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approach is derived from the fact that NPs, due to their particulate (as opposed to molecular) nature, can 
easily be directed to the tumor site by covalently linking tissue-specific molecular determinants or, in 
the case of magnetic NPs, with the aid of the external application of local magnetic fields. Therefore, 
such NPs can be used to selectively kill cancer cells, transforming radiant energy into heat or ROS.  
This helps reduce the damage to healthy tissues, which is among the most dangerous side effects of 
cancer therapy. 
The use of magneto-sensitive NP complexes comprised of NPs of iron oxide and the anticancer drug 
doxorubicin increases the antitumor effect compared to conventional doxorubicin therapy. This 
increased antitumor effect is probably due to the fact that an external magnetic field can induce electron 
transitions in the nanocomplexes. The magneto complexes have additional free radicals, and doxorubicin 
acquires the magnetic properties of paramagnetic substances. The antitumor drug action is based on the 
activation of the hydroxyl radicals, which break mitochondria, lipids, proteins, DNA and other structures 
in tumor cells, and finally leads to their apoptosis or necrosis. The combined effect of a constant magnetic 
field and moderate radio frequency-induced hyperthermia (below 40 °C) and a magneto-sensitive 
nanocomplex of iron oxide and paramagnetic doxorubicin increased antitumor and antimetastatic action, 
compared to conventional diamagnetic doxorubicin. The synergy of magnetic fields and an anticancer 
magneto-sensitive nanocomplex provides a new strategy for future effective treatments of cancer [8]. 
Spherical iron oxide NPs were approved in the EU as a medical device for magnetic tumor 
hyperthermia in brain [9,10] and prostate cancer [11], in combination with radiotherapy or  
chemotherapy [12]. Recently, it has been observed that heat-generating PEG-coated iron oxide 
nanocubes interfere with the extracellular matrix of a tumor and have the potential to destructure the 
matrix under magnetic stimuli. This results in NP redistribution in the tumor during the three-cycle 
heating procedure, which also leads to the diminution of tumor growth [13].  
Anticancer hyperthermia therapy consists in the application of heat at a temperature above 40 °C with 
the aim of killing tumor cells [14]. Different nanostructures have been used in hyperthermia applications, 
including magnetic iron oxide NPs. Once these nanomaterials are delivered to the tumor site, they 
efficiently absorb energy from an extrinsic source (e.g., NIR radiation or magnetic fields), transforming 
it into heat. Very promising results in hyperthermia treatments were obtained with magnetic iron oxide 
NPs, both in cell models and in vivo, as previously extensively reviewed [6]. When iron oxide NPs are 
exposed to radiofrequency oscillating magnetic fields, they produce heat due to the reorientation of the 
magnetization process. 
The magnetization of super-paramagnetic iron oxide NPs (SPIONs) disappears as soon as the 
magnetic field is removed [15]. This is very important, because magnetization induces NP aggregation: 
a phenomenon that is acceptable during the treatment, but very dangerous to the patient after the 
treatment, when large aggregates may hinder the clearance of NPs and create serious health hazards. For 
this reason, for in vivo hyperthermia applications, the iron oxide NPs must be below the 30–40 nm size 
limit, to avoid the formation of ferromagnetic NPs. An increase in particle size will lead to higher 
saturation magnetization values and better performance for magnetic hyperthermia applications. 
However, this is only true when the particle is smaller than a critical size above which magnetic NPs 
become ferromagnetic (the so-called super-paramagnetic limit), which, in principle, is undesired 
magnetic behavior for biomedical applications, due to potential particle aggregation. Meanwhile, 
particle size is an issue of crucial interest in many biomedical applications in which the use of very small 
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particles is highly desired, so that they can act as heat nano-sources in tumor regions of limited  
size access [16]. 
Recently, iron oxide NPs were studied as radio-sensitizing agents when using X-ray sources. In vitro 
studies showed that citrate- and malate-coated SPIONs sensitized tumor cells to X-rays by catalyzing 
ROS formation [17]. The results are promising and deserve further analysis of the biological mechanisms 
occurring downstream of the ROS production (Figure 1). 
 
Figure 1. Transmission electron microscopy (TEM) images of MCF-7 (A1,A2),  
3T3 (B1,B2) and Caco-2 (C1,C2) cells incubated in the presence of uncoated  
super-paramagnetic iron oxide NPs (SPIONs). The uncoated SPIONs were internalized via 
endocytosis in the Caco-2 cells (C1) and afterward released into the cytoplasm (C2).  
Citrate-coated SPIONs agglomerated in the cytoplasm of MCF-7 cells (A2) and were 
adsorbed along the endoplasmic reticulum in 3T3 cells (B2). Reproduced with permission 
from [17]. Copyright 2014, ACS Publications. 
1.2. Titanium Dioxide 
The principle behind photodynamic therapy (PDT) is that a photo-sensitizer (PS) consisting of a 
hydrophobic organic molecule is excited with electromagnetic radiation in the range of visible or UV 
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light to generate cytotoxic ROS that induce apoptosis. The earliest photodynamic therapy protocols 
made use of polymeric and inorganic NPs as passive carriers to improve the solubility of the hydrophobic 
PS molecules and as platforms for their delivery to the tumor site [18]. An alternative approach consists 
of the use of inorganic NPs, such as titanium oxide (TiO2) [19–21], as direct photo-sensitizing agents 
that can therefore be used in place of PS molecules. 
Photocatalyzed titanium dioxide (TiO2) NPs have been shown to eradicate cancer cells. However, the 
required in situ introduction of UV light limits the use of such therapy in humans. One strategy to 
overcome the limitations is the surface-functionalization of TiO2. Cell viability was observed to depend 
on particle concentrations, cell types and surface chemistry. Specifically, –NH2 and –OH groups showed 
significantly higher toxicity than –COOH. The results suggest that functionalized TiO2, and presumably 
other NPs, can be surface-engineered for targeted cancer therapy. In cancerous cell lines of T-24, HeLa 
and U937 cells, TiO2 particles were found to become incorporated into the cell membrane and  
the cytoplasm [20]. 
TiO2 NPs can be maintained for a long time in the body, and they are nontoxic and stable without 
light irradiation. A major challenge in photodynamic therapy is the direct illumination of the tissue by 
UV or visible light to trigger the TiO2 NPs. However, UV and visible light has a limited penetration 
distance in tissue, and this is a disadvantage when cancer cells are located far from the surface [22]. The 
maximum penetration into tissue can be obtained in the near-infrared (NIR) range (700–1000 nm), and 
this can be used for TiO2 NPs. Recently, the efficacy of NIR on crystallized shells composed of TiO2 
NPs coated on the surface of NaYF4:Yb3þ,Tm3þ@NaGdF4:Yb3þ cores to form (NaYF4:Yb3þ, 
Tm3þ@NaGdF4:Yb3þ)@TiO2 core/shell nanocomposites (denoted as UCNPs@TiO2 NCs) has  
been demonstrated. Considering the deeper tissue penetration of NIR light than UV light, 
UCNPs@TiO2-based NIR light-mediated PDT possesses more effective tumor inhibition in 
comparison with UV light-irradiated UCNPs@TiO2. These effects have been demonstrated on HeLa 
cells in vitro and in vivo in a tumor model using female Balb/c nude mice [23]. 
Other authors have reported the synthesis of core-shell upconversion nanoparticles (UCNs) with a 
thin and continuous layer of TiO2, as nanotransducers with the ability to convert low-energy NIR light 
to high energy, which can penetrate deeper into the tissue [24]. The same authors have reported 
recently the capacity of these synthesized UCNs to reduce the production of tumors in vivo developed 
by injection of oral squamous cell carcinoma (OSCC) [25]. 
1.3. Cerium Oxide Nanoparticles 
Cerium oxide NPs (CNPs) are a novel and very interesting material for radiation therapy, possessing 
the “smart” capacity to selectively induce the death of irradiated cancer cells [26], while protecting the 
surrounding tissue from radiation-induced damage and oxidative stress. Therefore, CNPs have the 
unique feature of acting as radio-protecting, as well as radio-sensitizing agents simultaneously. These 
NPs selectively increased oxidative stress and apoptosis in irradiated cancer cells, while protecting 
normal tissues [27,28]. It has been hypothesized that the selective toxicity of CNPs against cancer cells 
is due to the inhibition of the catalase-like activity of CNPs that occurs in acidic (pH 4.3) environments: 
in the presence of superoxide produced by the ionizing radiation, the SOD-like activity, which is 
maintained even at low pH, would lead to H2O2 accumulation, incrementing radiation toxicity [26]. The 
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hypothesis is based on the assumption that cancer cells are acidic. In fact, the cytosol of cancer cells is 
slightly more alkaline (pH > 7.4) than normal cells; whereas the extracellular tumor microenvironment 
is slightly acidic due to the Warburg effect, and the pH decreases from 7.1 (normal tissues) down  
to 6.7 [29]. 
Another possible mechanism for the differential toxicity of CNPs on cancer cells would involve their 
SOD-like activity. It is known from many studies that the SOD enzyme acts as a radio-sensitizing agent, 
potentiating the DNA damage response and delaying the G2/M transition, thus favoring cell 
accumulation in G2 and allowing more thorough DNA repair. Therefore, CNPs may act as  
radio-sensitizing agents through an additional, biological mechanism that controls the response to  
DNA damage [30]. 
Recent results show that CNPs are almost as toxic as radiotherapy to the pancreatic cancer cells 
L3.6pl, but showed little or no toxic effect on the normal cells hTERT-HPNE. This finding points to the 
use of these NPs as a stand-alone therapy for pancreatic cancer treatment [26]. 
A recent study compared the effect of CNPs on cancer and normal human cells and concluded that 
the toxicity of these NPs is specific to the cancer cells. The low inhibitory potential of cerium oxide in 
normal human cell lines indicates that they may be safer for human usage in industry and medicine [31]. 
Other studies have shown that redox-active CNPs exhibit cytotoxic and anti-invasive effects on 
several cancer cells and are capable of sensitizing tumor cells to radiation, while protecting the normal 
cells in the stroma surrounding a tumor [32]. In squamous cell carcinoma of the skin and melanoma, 
CNPs exhibit pro-apoptotic and anti-invasive effects in a ROS-dependent manner. In contrast to 
conventional chemotherapeutics, CNPs are nontoxic to healthy, stromal cells of the skin. It has been 
reported that CNPs exert either pro-oxidant or antioxidant redox activity. Although CNP treatment 
increases the ROS level in tumor cells, resulting in apoptosis, CNPs showed antioxidant and protective 
properties in normal cells [33]. A medical application of CNPs may provide a promising possibility for 
skin cancer therapy and may be a valuable tool to supplement classical chemotherapeutics, such as 
doxorubicin, and protect against doxorubicin-induced cytotoxicity. Another advantage of CNPs is that 
they do not present genotoxic effects [34]. These results with CNPs of 5 nm are in contrast to another 
recent study with CNPs with a size of 16–22 nm, where DNA damaging effects were found in other 
tumor cell lines [32], indicating that the mode of action of the nanoparticles is strongly dependent on the 
size and cell type. The supplementation of conventional chemotherapies with CNPs may offer a novel 
strategy in the treatment of cancer, with greater benefit for patients, by enhancing antitumor activity and 
lowering the damaging side effects [34]. 
Previous studies were done in vitro, and it is necessary to demonstrate in vivo the efficacy of 
nanoparticles in the treatment of tumors. In this sense, in vivo xenograft studies with immunodeficient 
nude mice showed a decrease of tumor weight and volume after treatment with CNPs. This effect could 
be attributed to redox-active CNPs, which present selective pro-oxidative and antioxidant properties. 
This study was the first to show that CNPs prevent tumor growth in vivo [35]. 
1.4. Zinc Oxide Nanoparticles 
Application of ZnO NPs, has shown that they are most efficacious on T98G cancer cells, moderately 
effective on KB cells and least toxic on normal human HEK cells. These results demonstrated that 
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treatment with ZnO NPs sensitizes T98G cells by increasing both mitotic (linked to cytogenetic damage) 
and interphase (apoptosis) death. The ZnO NPs behave as genotoxic drugs, since they induce 
micronucleus formation in cells. These results could be helpful in designing more potent anticancer 
agents for therapeutic uses [36]. 
The apoptosis-correlated, intracellular production of ROS was also measured with melanoma cancer 
cells with varying ZnO NP doses [37]. 
Zinc oxide NPs were used at a very low concentration and were found to exhibit activity against 
HepG2 (liver cancer) and MCF-7 (breast cancer) cancer cells in a dose-dependent manner: viability, 
measured by the MTT assay, showed a dose-dependent decrease. At a very low concentration, such as 
25 µg/mL, the cell viability was less than 10% in the case of HepG2 cells (Figure 2). The results of these  
anti-proliferative studies clearly demonstrate that treatments with NPs sensitize cancer cells. The degree 
of apoptosis was found to be enhanced with an increase in the concentration of NPs, and a significant 
concentration of NPs resulted in cell death in both cancer cell lines [38]. In that study, quantitative  
real-time PCR was utilized to analyze the mRNA levels of apoptotic markers (p53, Bax, bcl-2 and 
caspase-3) in HepG2 cells exposed to ZnO NPs at a concentration of 50 μg/mL for 24 h. The results 
showed that the mRNA levels of these apoptotic markers were significantly altered in HepG2 cells due 
to ZnO NP exposure. The mRNA level of the tumor suppression gene p53 was 1.9-fold higher and the 
mRNA expression levels of the pro-apoptotic gene Bax and the anti-apoptotic gene bcl-2 were decreased 
(2.7- and 2.5-fold, respectively) in the exposed cells, compared to untreated cells. Moreover, the effect 
of ZnO NPs on the mRNA expression level of caspase-3 was studied and was found to be 1.8-fold higher 
in the treated cells than the untreated control cells. The mRNA expression levels of p53, Bax, bcl-2 and 
caspase in HepG2 cells in response to ZnO NP exposure was studied, because apoptosis is controlled 
through these pathways. The quantitative real-time PCR results show that ZnO NPs upregulate the 
mRNA levels of the cell cycle checkpoint protein p53 and the pro-apoptotic protein Bax. The expression 
of the anti-apoptotic protein bcl-2 was downregulated in cells exposed to ZnO NPs. Furthermore, the 
upregulation of p53 and the downregulation of bcl-2 family members, such as Bax, induce the 
permeabilization of the outer mitochondrial membrane, which releases soluble proteins from the 
intermembrane space into the cytosol, where they promote caspase activation [38]. 
Therapeutic cancer vaccines are emerging as part of an anticancer regimen that utilizes specific 
antigens to initiate and modulate the antitumor immune response [39]. Dendritic cells (DCs) have been 
used for therapeutic cancer vaccines [40]. DC-based cancer immunotherapy that destroys tumors 
requires a clinically-suitable delivery system for the target antigens in the DCs. In one study, the authors 
developed iron oxide (Fe3O4)-zinc oxide (ZnO) core-shell NPs (CSNPs) to have ZnO-binding peptides 
to carry tumor antigens in DCs. This NP-antigen complex was efficiently taken up by the DCs and was 
demonstrated to function as a cancer immunotherapy via injection of the DCs containing the  
CSNP-antigen complex into the hind footpads of mice. Mice immunized with DCs containing the  
NP-antigen complex showed enhanced tumor antigen-specific T-cell responses, delayed tumor growth 
and better survival than controls [41]. However, a study of the potential toxicity of these new 
nanocarriers is required. Recently, a repeated toxicity study was performed in vivo by subcutaneous 
injection in mice and showed a dose-dependent increase in granulomatous inflammation at the injection 
site of the CSNP-treated animals, but no alterations in the body (Figure 3) and other histopathological 
lesions in other organs could be attributed to the CSNPs [42]. 
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Figure 2. Microscopic images of HepG2 cells after treatment with ZnO NPs and the 
mitochondrial activity of cells exposed to various concentration of ZnO NPs for 24 and  
48 h. The values are the mean ± SD of three independent experiments. * p < 0.01 and  
** p < 0.001 vs. the control group (each scale bar = 1 mm). Reproduced with permission 
from [38]. Copyright 2014, Elsevier. 
The electrostatic properties of zinc oxide determine that it can have different charges on its surface 
under acid and base conditions. This can be used in the conjugation of therapeutic agents and also to 
internalize NPs within cancer cells, as they are high in phospholipids with negative charges on their 
surface. Zinc oxide NPs also have a photodynamic property: illumination leads to the production of large 
amounts of ROS and can result in cell apoptosis [43]. These qualities make zinc oxide NPs a suitable 
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candidate for a drug carrier. Conjugation of therapeutic agents with zinc oxide NPs may yield better 
results than with other NPs, in the targeted cancerous cells instead of normal cells. 
 
Figure 3. Body weight (A), body weight gain (B), food (C), and water (D) consumption in 
mice injected with core-shell NPs (CSNPs) for four weeks. Reproduced with permission 
from [42]. Copyright 2015, John Wiley & Sons, Ltd. 
The decrease in cell viability of MCF-7 cell lines after treatment with a metalloprotein confirms that 
synthesized metalloproteins can have an anticancer property. NPs carrying asparaginase were found to 
be more specific, highly effective and to provide reliable results [44]. 
ZnO NP pre-incubation followed by UVA-1 irradiation induced a significant reduction in viable head 
and neck squamous cell carcinoma cell lines (HNSCC) in vitro [45]. 
One strategy to reduce the toxicity of typical cancer therapies is their combination with NPs. The 
combination of ZnO NPs with paclitaxel and cisplatin [46] or daunorubicin [47] increases the effect of 
these chemotherapeutics in cell lines in vitro. It is evident that differently-sized ZnO NPs could greatly 
facilitate drug targeting and accumulation of daunorubicin in leukemia cancer cells and could thus act 
as an efficient agent to enhance drug delivery [47]. 
The combination of NPs with typical cancer drugs allows the reduction of the drug dose with the 
corresponding reduction in side effects. 
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1.5. Copper Oxide Nanoparticles 
Studies report the biosynthesis of copper oxide NPs (CONPs) from different plant extracts, such as 
that of Ficus religiosa [48] or Acalypha indica [49]. These NPs showed cytotoxic effects on A549 human 
lung cancer cells and MCF-7 breast cancer cells, respectively. The mechanism of cytotoxicity was 
demonstrated to be through the induction of apoptosis with enhanced ROS generation. The green 
synthesis of these NPs has been proposed as a reliable, simple, nontoxic and eco-friendly method [50]. 
CONPs have many industrial applications [51], but recent studies have reported the antifungal and 
bacteriostatic properties of copper NPs/polymer composites [52]. 
In vitro studies demonstrated that cuprous oxide nanoparticles (CONPs) selectively induce the 
apoptosis of tumor cells in vitro [53]. Thereafter, the same authors studied the antitumor properties of 
CONPs in vivo, using the particles to treat mouse subcutaneous melanoma and metastatic lung tumors, 
based on B16-F10 mouse melanoma cells, by intratumoral and systemic injections, respectively. The 
results showed that CONPs significantly reduced the growth of melanoma, inhibited the metastasis of 
B16-F10 cells and increased the survival rate of tumor-bearing mice. The subcutaneous tumors of the 
CONP group were clearly smaller than those observed in the glucose control group (Figure 4). To 
explore the clearance of CONPs, mice were injected with particles via the vena caudalis at a dose of  
2 mg/kg, and after seven days, the major organs were harvested and observed. Importantly, the results 
also indicated that CONPs were rapidly cleared from the organs and that the particles exhibited little 
systemic toxicity. 
 
Figure 4. Antitumor effects of copper oxide NP (CONP) therapy on subcutaneous melanoma 
and metastatic lung tumors. (a) Representative images of stripped subcutaneous tumors;  
(b) Representative images of mice bearing subcutaneous melanoma from the same study at 
Day 12; (c) Plot of tumor mass versus time. Reproduced with permission from [54]. 
Copyright 2015, Associazione Differenziamento e Morte Cellulare. 
Furthermore, the authors observed that CONPs targeted the mitochondria of HeLa cells in vitro, 
which resulted in the release of cytochrome C from the mitochondria and the activation of caspase-3 and 
caspase-9 after the CONPs entered the cells. In conclusion, CONPs can induce the apoptosis of cancer 
cells through a mitochondrion-mediated apoptosis pathway, which raises the possibility that CONPs 
could be used to cure melanoma and other cancers. CONPs inhibit the growth and metastasis of 
melanoma in a tumor-bearing mice model and are rapidly cleared by mice with low toxicity [54]. 
CONPs were found to induce cytotoxicity in a human liver carcinoma cell line (HepG2) in a  
dose-dependent manner, which was probably mediated through ROS generation and oxidative stress [55].  
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1.6. Silicon Dioxide or Silica 
In contrast to other metal oxide NPs with antitumor effects per se, silica has been shown to be a good 
carrier for different anticancer drugs, such as gemcitabine and paclitaxel, in the treatment of pancreas 
cancer in mice [56]. 
The size- and shape-controllable pores of mesoporous silica NPs (SNPs) can store pharmaceutical 
drugs and prevent their premature release and degradation before reaching their designated target. 
Chemotherapeutic drugs can be loaded into mesoporous silica NPs, replacing the need to use solvents 
that are often toxic for healthy tissues. 
The first concern is the potential toxicity of this kind of NP; so it is necessary to study subacute 
toxicity with mesoporous SNPs. This study showed no toxicity after in vivo administration to  
mice [57]. Thereafter, the authors reported the design, synthesis and biological evaluation of  
surface-modified SNPs for the delivery of camptothecin (CPT). The tumors in the mice treated with 
NPs loaded with CPT were virtually eliminated at the end of the experiments. These results proved 
that the high drug-loading capacity, low toxicity and tumor-accumulating effect of these NPs provide 
a promising drug delivery vehicle for anticancer drugs. The tumor-curing results were also 
encouraging, constructing a base for further research into the capacity of MSNs for other types of 
tumors and the possibility of using lower dosages to further reduce toxicity. SNPs have a natural 
tendency to aggregate, due to hydrogen-bond interactions between external silanol groups. The use of 
this type of nanomaterial in biological applications requires the reduction of this natural trend, in order 
to improve biodistribution and cellular uptake. Coating the NP surface with trihydroxysilylpropyl 
carboxylate (THSC) groups has a considerable effect on the surface charge of SNPs (−1.8 and −13.9 mV 
for non-coated SNP and SNP-COOH, respectively) with the electrostatic repulsion being enough to 
reduce aggregation and to increase the stability of the particles in aqueous solution [58]. A drug has 
been covalently linked to the NP through an ester bond with the 20-hydroxy moiety, in order to 
stabilize its lactone ring and to avoid unspecific release of the drug. The material obtained is highly 
stable in plasma, with slow release of the cargo at physiological pH values. Cell internalization and  
in vitro efficacy assays demonstrated that SNPs carrying CPT entered cells via endocytosis, and the 
intracellular release of the cargo induced cell death with half maximal inhibitory concentration (IC50) 
values and cell cycle distribution profiles similar to those observed for the naked drug. Furthermore, the 
in vivo biodistribution, therapeutic efficacy and biocompatibility of the SNP-CPT were evaluated in 
human colorectal cancer xenografts using in vivo fluorescence or bioluminescence optical imaging.  
In vivo tumor-accumulation and whole-body tissue distribution were studied based on the acquisition of 
fluorescence emission of a fluorophore (Cy5.5) conjugated to the SNP-CPT, as well as by HPLC 
quantification of tissue CPT levels. The results showed that although the SNP-CPT tended to 
accumulate in organs of the reticuloendothelial system, the SNPs boost CPT concentration in tumor 
compared to administration of the free drug. Accordingly, SNP-CPT treatment delayed the growth of 
subcutaneous tumors while significantly reducing the systemic toxicity associated with CPT 
administration. These results indicate that SNP-CPT could be used as a robust drug delivery system 
for antitumor treatments based on CPT [59]. The authors indicated that although their results regarding 
tumor growth differences were not as dramatic as those obtained previously by Lu et al. [57], a distinct 
type of experiment was carried out in each case. Botella et al. [58] performed a tumor growth inhibition 
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experiment starting treatment once the tumors were well established; in contrast, Lu et al. performed 
a tumor growth prevention assay, and the therapeutic agents were also administered at higher doses 
via a different route [59]. 
1.7. Influence of Size and Characteristics of Nanoparticles 
Different strategies have been developed for cancer treatment; the first exploits the enhanced 
permeation and retention effect (EPR) associated with the hyperpermeability of the tumor vasculature 
where sufficiently small particles (<500 nm) can passively extravasate and accumulate in tumor 
parenchyma [60]. 
The size of the different metal oxide nanoparticles appears in Tables 1 and 2, where we can observe 
that in most cases, the particles are smaller than 50 nm. The measures of the NPs are usually performed 
in water, but when NPs are in cell culture medium, aggregates are observed. This is one of the principal 
limitations in knowing the real size of NPs when in vitro studies are performed. 
Table 1. Metal oxide NPs with anticancer activity by direct action on tumor cells in different 
in vivo models. 
Metal Oxide NPs In Vivo Model NP Size Authors Reference
Cerium oxide 
Orthotopic injection of pancreatic 
cancer cells in athymic nude mice 
5–8 nm Wason et al., 2013 [26] 
Cerium oxide 
Xenografted mice injected with 
melanoma cells 
3–5 nm Ailili et al., 2013 [35] 
Titanium dioxide 
Human oral squamous cell 
carcinoma tumor in mice 
50 nm Lucky et al., 2015 [25] 
Copper oxide Subcutaneous melanoma in mice 40–110 nm Wang et al., 2013 [54] 
The uptake, localization and effect of cerium oxide nanoparticles in the cells depend on their size, 
surface charge and agglomeration inside the cells. Particles of a diameter less than 20 nm are present 
longer in the cells than larger particles. The uptake of single, unagglomerated nanoparticles therefore 
becomes very improbable for particles of less than 50 nm in size; then, particle size is indirectly the 
dominant factor determining the rate of uptake, while primary particle number concentration and total 
surface area are of minor importance [31,61]. 
Studies reporting the use of TiO2 in photodynamic therapy have presented a nonuniform size of the 
nanoconstruct that might have compromised repeatability and translatability of photodynamic therapy 
results in vivo [25]. 
When NPs are administered in vivo and are present in blood, then protein corona can be formed, 
modifying their action. NP-protein coronas generally reduce cytotoxicity and immunotoxicity, but 
immunotoxicity can be mitigated or activated depending on the type of NP and adsorbed plasma protein. 
At this time, there is limited knowledge of the correlation between the physicochemical properties of 
NPs and their physiological effects. The formation and immunological response to NP-protein coronas 
is significantly influenced by the physiochemical surface properties of the NPs (i.e., physical surface 
architecture and chemical functionality), and thus, future works should address this by analyzing protein 
distribution and examining in vitro and in vivo responses [62]. 
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Table 2. Metal oxide NPs with anticancer activity by direct action on tumor cells in different 
in vitro studies. HNSCC, head and neck squamous cell carcinoma. 
Metal Oxide In Vitro Model NP Size Organ Origin Authors Reference 
Cerium oxide 
Pancreatic  
cancer cell line L3.6pl 
5–8 nm Pancreas 
Wason et al., 
2013 
[26] 
Cerium oxide 
Non-small cell carcinoma  
NCI-H460  
DLD1 and HT-29 
adenocarcinoma 
4 nm 
Lung 
colon/rectum 
Pešić et al., 
2015 
[31] 
Cerium oxide A375 melanoma cells 5 nm Skin 
Sack et al., 
2014 
[32] 
Cerium oxide 
Squamous carcinoma cell lines 
SCL-1 
3–5 nm Skin 
Ailili et al., 
2013 
[35] 
Copper oxide 
HeLa cells from human 
cancerous cervical tumor and 
B16-F10 melanoma cells  
from mice 
40–110 nm Cervix skin 
Wang et al., 
2013 
[54] 
Copper oxide HepG2 cells 22 nm Liver 
Sidiqqui et 
al., 2013 
[54] 
Copper oxide 
A549 adenocarcinomic human 
alveolar basal epithelial cells 
577 nm Lung 
Sankar et al., 
2014 
[48] 
Iron oxide 
Caco-2 cells  
MCF-7 cells 
9–20 nm Colon breast 
Klein et al., 
2014 
[17] 
Titanium 
oxide 
Human bladder cancer cell line 
T24, HeLa and human myeloid 
leukemia cell line U937 
21 nm Bladder blood 
Thevenot  
et al., 2008 
[20] 
Zinc oxide 
T98G human  
glioblastoma cells 
13 nm Brain 
Wahab et al., 
2013a 
[36] 
Zinc oxide HNSCC carcinoma cell lines 74 nm Neck 
Hackenbert  
et al., 2010 
[45] 
2. Conclusions 
Different strategies use metal oxide NPs in the treatment of cancer. In some cases, the NP alone  
shows antitumor effects, both in vitro and in vivo, by direct action on tumor cells or indirectly via the 
action of heat. 
In other cases, the NPs could facilitate the action of a typical anticancer drug, reducing the dose 
required and the side effects that are the principal disadvantage of such drugs. 
Several studies demonstrated the antitumor activity of different metal oxide nanomaterials in vitro 
and only a few studies in vivo; the latter showing the action of cerium oxide (CNPs) and cuprous  
oxide (CONPs) nanoparticles. Recently, the effect of titanium dioxide (TiO2) stably coated on 
individual UCN cores with the application of NIR to penetrate tumors of OSCC induced in mice has 
been demonstrated. 
In conclusion, there has been an increase in recent years in the research of the potential use of metal 
oxide NPs for cancer treatment. However, there are still limitations due to the heterogeneity of the cell 
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used for each tumor model in vitro and/or in vivo, which make it difficult to do a comparison between 
the different studies. Another limitation is the formation of protein corona when NPs reach the blood 
and interact with the plasma proteins, affecting in vivo distribution and clearance. Research continues 
in this area, and more information about the distribution, biocompatibility and low toxicity for normal 
tissues is necessary prior to clinical trials. 
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